Bureau of Pharma PSUs of India

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Government of India)

No. BPPI/Drug- 056/2018

dated 03/10/2018

ORDER

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi had published tender no. BPPI/Drugs- 056/2018 dated 26/02/2018 through e-procurement system i.e., CPP portal on 26/02/2018 for supply of drugs for the year 2018-2020.

Whereas, M/S TERRACE PHARMACEUTICALS PVT. LTD. (here after called as the firm) address at F-67, PHASE-VII, INDUSTRIAL AREA, MOHALI had participated in tender. The firm was awarded 03 drugs by Bureau of Pharma Public Sector Undertakings of India, New Delhi vide letter dated 16/07/2018 of acceptance for price agreement for supply of 03 drugs for 2 years period as per tender provision. The firm was asked to submit performance security for Rs 1279740/- within 15 days as per clause 10 of tender document.

Whereas, the firm had not submitted performance security amount Rs. 1279740/-as per details above.

Whereas, Bureau of Pharma Public Sector Undertakings of India, New Delhi issued Show cause notice on 24/08/2018 to the firm informing about the clause no. 10.4, & 20.1(a) of tender document with request to explain within 7 days why not following actions against them may be taken: -

- (i) Forfeit of EMD of Rs.100000/- submitted by the firm in form of BG No. 4089OBG18005411 issued by Kotak Mahindra Bank.
- (ii) Initiate blacklisting of your company.

The firm have replied vide their email dated 24.08.2018 & requested to clear their old dues. It was noted by Bureau of Pharma Public Sector Undertakings of India that recovery is due from the firm due to supply of NSQ drug, namely, Pregabalin Capsule 75 mg (DC -1107). Therefore, their old dues have not been cleared.

In view of above, the firm is debarred for a period of 2 years to participate in the tender of Bureau of Pharma Public Sector Undertakings of India, New Delhi for supply of all drugs from date of issuance of this order. Further, EMD of Rs. 1 lakh will be forfeited as per tender provisions.

This order is without prejudice to the legal and criminal action to be taken if any, by Bureau left Pharma Public Sector Undertakings of India, New Delhi in the matter.

Sachin Singh(IRS)

Chief Executive Officer

Bureau of Pharma PSUs of India, New Delhi

То

Regd